Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
暂无分享,去创建一个
Bing-he Xu | Q. Sun | Shiying Yu | N. Liao | Xiaojia Wang | R. Luo | Xichun Hu | Qingyuan Zhang | S. Cui | Donggeng Liu | H. Zheng | Hong Zheng